CMVIBE TRIAL Summary: A phase 1/2A open-label dose-ranging and observer-blind placebo-controlled, safety and immunogenicity study of mRNA-1647 Cytomegalovirus vaccine in female and male participants 9 to 15 years of age and participants 16 to 25 years of age.

read more